Clinical trials: Oncologic
Gynaecological Malignancies
A Study of SHR-A1811 in Subjects With Gynaecologic Oncology
This is an open-label, two-part study to evaluate the safety and efficacy of SHR-A1811 for injection in subjects with a gynaecological malignancies.
- Trial name
- NCT05896020
- Testing
- SHR- A1811
- Where
- China
- Volunteers
- 225 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Cancer
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Durvalumab
The rationale of the ROSY-D study is to continue to provide study treatment for patients who have participated in a parent study with Durvalumab and who are continuing to derive clinical benefit from treatment at the end of such…
- Trial name
- ROSY-D (NCT05303532)
- Testing
- Durvalumab
- Where
- 123 sites in United States, Argentina and 29 more
- Volunteers
- 214 people
- Sponsor
- AstraZeneca
Neuroendocrine Tumors, Pancreatic Neuroendocrine Tumor
Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors
CVM-1118 (TRX-818) is a new small molecule chemical entity being developed as a potential anti-cancer therapeutic by TaiRx, Inc. CVM-1118 is a potent anti-cancer agent in numerous human cancer cell lines.
- Conditions
- Neuroendocrine Tumors, Pancreatic Neuroendocrine Tumor, Gastro-enteropancreatic Neuroendocrine Tumor, Lung Neuroendocrine Neoplasm
- Trial name
- NCT03600233
- Testing
- CVM-1118
- Where
- 8 sites in Taiwan
- Volunteers
- 34 people
- Sponsor
- TaiRx, Inc.
Advanced Cancer
C14 Study in Oncology Patients With Advanced and/or Metastatic Solid Tumors
This is an open-label study being conducted to determine the metabolism and physiological disposition of radiolabeled LY2603618 after a single dose in patients with advanced and/or metastatic solid tumors.
- Trial name
- NCT01296568
- Testing
- LY2603618, Pemetrexed, Gemcitabine
- Where
- Switzerland
- Volunteers
- 3 people
- Sponsor
- Eli Lilly and Company
HNSCC
Intratumoral Microdosing of Motolimod in HNSCC
This is a multi-center, single arm, open-label, multi-agent, localized pharmacodynamic biomarker Phase 0 trial designed to study the biological effects within the tumor microenvironment of motolimod and motolimod combined with…
- Trial name
- NCT04272333
- Testing
- Motolimod, Nivolumab, Motolimod + Nivolumab
- Where
- 5 sites in United States
- Volunteers
- 1 people
- Sponsor
- Presage Biosciences
Melanoma
A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma
The study design included an open-label, dose escalation phase followed by a blinded, randomized phase, which combined epacadostat (an oral IDO1 inhibitor) with an approved therapy and compared to approved therapy plus placebo in…
- Trial name
- NCT01604889
- Testing
- Epacadostat, ipilimumab
- Where
- 7 sites in United States
- Volunteers
- 50 people
- Sponsor
- Incyte Corporation